Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia


ELİAÇIK E., Isik A., Aydin C., ÜNER A., AKSU S., SAYINALP N., ...More

HEMATOLOGY, vol.20, no.7, pp.392-396, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 7
  • Publication Date: 2015
  • Doi Number: 10.1179/1607845414y.0000000221
  • Journal Name: HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.392-396
  • Hacettepe University Affiliated: Yes

Abstract

Objectives: The aim of this study was to assess bone marrow (BM) fibrosis and dysplasia in chronic myeloid leukemia (CML) patients receiving the first-generation tyrosine kinase inhibitor (TKI), imatinib, or secondgeneration TKIs, dasatinib, and nilotinib. We further investigated whether CML under TKI is associated with dysplastic BM changes during the clinicopathological course of the disease.